Dysregulation of PLA2 activity has been demonstrated in multiple diseases, including cancer, rheumatoid arthritis, and psoriasis (Leistad et al., 2011; Linkous and Yazlovitskaya, 2010; Magrioti and Kokotos, 2013), and drugs targeting PLA2s are being considered for treating mostly inflammatory diseases (Nikolaou and Kokotos, 2018). This evidence concerns the gene PLA2G6 and psoriasis.